Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11 juin 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
03 juin 2024 16h02 HE
|
Rhythm Pharmaceuticals, Inc.
Rhythm presents first-ever hypothalamic obesity patient-reported experiences with hyperphagia and positive changes in energy and sleep at ENDO2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03 juin 2024 08h02 HE
|
Rhythm Pharmaceuticals, Inc.
RYTM CEO at David Meeker at Goldman Sachs Global Healthcare Conference June 10.
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
22 mai 2024 04h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09 mai 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
07 mai 2024 07h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
06 mai 2024 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo...
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
29 avr. 2024 18h30 HE
|
Rhythm Pharmaceuticals, Inc.
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal...
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
24 avr. 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
16 avr. 2024 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...